{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:35:53Z","timestamp":1773916553164,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Heilongjiang Provincial Development and Reform Commission","award":["(2011) 1570"],"award-info":[{"award-number":["(2011) 1570"]}]},{"DOI":"10.13039\/501100002553","name":"Heilongjiang Education Department of Science and Technology Research Project","doi-asserted-by":"publisher","award":["12521z004"],"award-info":[{"award-number":["12521z004"]}],"id":[{"id":"10.13039\/501100002553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["J1210069\/J0106"],"award-info":[{"award-number":["J1210069\/J0106"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabet-metabolism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.diabet.2014.09.001","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T21:16:52Z","timestamp":1413235012000},"page":"82-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db\/db mice"],"prefix":"10.1016","volume":"41","author":[{"given":"X.","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2014.09.001_bib0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","article-title":"Identification of a novel FGF, FGF-21, preferentially expressed in the liver","volume":"1492","author":"Nishimura","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.diabet.2014.09.001_bib0010","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2014.09.001_bib0015","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.2337\/db05-1435","article-title":"Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1\/2 and Akt signaling pathways","volume":"55","author":"Wente","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2014.09.001_bib0020","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/mc.20241","article-title":"Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis","volume":"45","author":"Huang","year":"2006","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.diabet.2014.09.001_bib0025","first-page":"1089","article-title":"Cloning, expression and purification of mouse fibroblast growth factor-21 and its function in adipocyte glucose metabolism","volume":"39","author":"Jiang","year":"2012","journal-title":"Prog Biochem Biophys"},{"key":"10.1016\/j.diabet.2014.09.001_bib0030","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.diabet.2014.09.001_bib0035","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1021\/bc060245m","article-title":"Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity","volume":"18","author":"Lee","year":"2007","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.diabet.2014.09.001_bib0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1386207053258578","article-title":"Phage display and PEGylation of therapeutic proteins","volume":"8","author":"Mukai","year":"2005","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1016\/j.diabet.2014.09.001_bib0045","doi-asserted-by":"crossref","first-page":"e20669","DOI":"10.1371\/journal.pone.0020669","article-title":"A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol","volume":"6","author":"Huang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.diabet.2014.09.001_bib0050","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2174\/1389201015666140515124838","article-title":"Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation","volume":"14","author":"Ye","year":"2014","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.diabet.2014.09.001_bib0055","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.diabres.2010.01.020","article-title":"Glucose control in patients with type 2 diabetes based on frequency of insulin glargine administration","volume":"88","author":"Housel","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabet.2014.09.001_bib0060","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.2337\/diabetes.49.12.2142","article-title":"Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro","volume":"49","author":"Lepore","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2014.09.001_bib0065","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2337\/diacare.23.6.813","article-title":"Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites","volume":"23","author":"Owens","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2014.09.001_bib0070","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/diacare.24.4.631","article-title":"Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin","volume":"24","author":"Rosenstock","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2014.09.001_bib0075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-2003-39080","article-title":"A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes","volume":"35","author":"Massi Benedetti","year":"2003","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.diabet.2014.09.001_bib0080","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2337\/diacare.23.8.1130","article-title":"Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes","volume":"23","author":"Yki-J\u00e4rvinen","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2014.09.001_bib0085","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3724\/SP.J.1206.2009.00238","article-title":"FGF21 improves glucose uptake and glycogen synthesis of insulin-resistant liver cells","volume":"36","author":"Liu","year":"2009","journal-title":"Prog Biochem Biophys"},{"key":"10.1016\/j.diabet.2014.09.001_bib0090","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc09-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"32","author":"American Diabetes Association","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2014.09.001_bib0095","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.clinthera.2007.06.018","article-title":"Dosing of insulin glargine in the treatment of type 2 diabetes","volume":"29","author":"Barnett","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.diabet.2014.09.001_bib0100","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1463-1326.2000.00085.x","article-title":"Physiology of glucose homeostasis","volume":"2","author":"Gerich","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2014.09.001_bib0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2014.09.001_bib0110","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/j.clinthera.2009.11.034","article-title":"A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus","volume":"31","author":"Montanya","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.diabet.2014.09.001_bib0115","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.clinthera.2013.03.021","article-title":"Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8mg or twice-daily exenatide 10\u03bcg","volume":"35","author":"Malmen\u00e4s","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.diabet.2014.09.001_bib0120","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","article-title":"Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial","volume":"375","author":"Diamant","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2014.09.001_bib0125","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.diabres.2007.09.013","article-title":"Insulin glargine-based therapy improves glycaemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies","volume":"79","author":"Davies","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabet.2014.09.001_bib0130","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"Coskun","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.diabet.2014.09.001_bib0135","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice","volume":"58","author":"Xu","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2014.09.001_bib0140","doi-asserted-by":"crossref","first-page":"e49345","DOI":"10.1371\/journal.pone.0049345","article-title":"Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes","volume":"7","author":"Hecht","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.diabet.2014.09.001_bib0145","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/S0021-9258(17)40292-4","article-title":"Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J Biol Chem"},{"key":"10.1016\/j.diabet.2014.09.001_bib0150","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.diabet.2014.09.001_bib0155","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.bioeng.2007.10.002","article-title":"Effect of site-directed PEGylation of trichosanthin on its biological activity, immunogenicity, and pharmacokinetics","volume":"24","author":"An","year":"2007","journal-title":"Biomol Eng"},{"key":"10.1016\/j.diabet.2014.09.001_bib0160","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.bbrc.2010.12.021","article-title":"Effect of alogliptin, pioglitazone and glargine on pancreatic \u03b2-cells in diabetic db\/db mice","volume":"404","author":"Kawashima","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.diabet.2014.09.001_bib0165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.physbeh.2014.02.036","article-title":"Antidepressant effects of insulin in streptozotocin induced diabetic mice: modulation of brain serotonin system","volume":"129","author":"Gupta","year":"2014","journal-title":"Physiol Behav"},{"key":"10.1016\/j.diabet.2014.09.001_bib0170","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1210\/mend.14.7.0470","article-title":"Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray","volume":"14","author":"Feng","year":"2000","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.diabet.2014.09.001_bib0175","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","article-title":"Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice","volume":"17","author":"Lin","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabet.2014.09.001_bib0180","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/90984","article-title":"The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.diabet.2014.09.001_bib0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1172\/JCI200317797","article-title":"The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice","volume":"112","author":"Xu","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2014.09.001_bib0190","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/gut.2009.199661","article-title":"Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications","volume":"59","author":"Stickel","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.diabet.2014.09.001_bib0195","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2004-1024","article-title":"Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease","volume":"90","author":"Angelico","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2014.09.001_bib0200","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1464-5491.1999.00166.x","article-title":"A desktop guide to type 2 diabetes mellitus","volume":"16","author":"European Diabetes Policy Group","year":"1999","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabet.2014.09.001_bib0205","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/dc07-S004","article-title":"Standards of medical care in diabetes \u2013\u00a02007","volume":"30","author":"American Diabetes Association","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2014.09.001_bib0210","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2337\/db08-1470","article-title":"Targeting hepatic glucokinase in type\u00a02 diabetes: weighing the benefits and risks","volume":"58","author":"Agius","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2014.09.001_bib0215","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/jcp.24133","article-title":"Suppression of GLUT1; a new strategy to prevent diabetic complications","volume":"228","author":"Lu","year":"2013","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.diabet.2014.09.001_bib0220","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2337\/diabetes.50.8.1901","article-title":"Defective insulin-induced GLUT4 translocation in skeletal muscle of high fat-fed rats is associated with alterations in both Akt\/protein kinase B and atypical protein kinase\u00a0C (zeta\/lambda) activities","volume":"50","author":"Tremblay","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2014.09.001_bib0225","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1172\/JCI117733","article-title":"High levels of glucose-6-phosphatase gene and protein expression reflect an adaptive response in proliferating liver and diabetes","volume":"95","author":"Haber","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2014.09.001_bib0230","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3724\/SP.J.1206.2012.00007","article-title":"Stability and glucose regulation of FGF21 after modified with arginines","volume":"39","author":"He","year":"2012","journal-title":"Prog Biochem Biophys"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363614001402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363614001402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T22:26:41Z","timestamp":1650407201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363614001402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1262363614001402"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2014.09.001","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db\/db mice","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2014.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}